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a subset of Patients with acute 
Myeloid leukemia has leukemia 
cells characterized by chemokine 
responsiveness and altered 
expression of Transcriptional as  
well as angiogenic regulators
Annette K. Brenner1*, Håkon Reikvam2 and Øystein Bruserud1,2
1 Section for Hematology, Department of Clinical Science, University of Bergen, Bergen, Norway, 2 Department of Medicine, 
Haukeland University Hospital, Bergen, Norway
Acute myeloid leukemia (AML) is an aggressive and heterogeneous bone marrow 
 malignancy, the only curative treatment being intensive chemotherapy eventually in com-
bination with allogeneic stem cell transplantation. Both the AML and their neighboring 
stromal cells show constitutive chemokine release, but chemokines seem to function as 
regulators of AML cell proliferation only for a subset of patients. Chemokine targeting is 
therefore considered not only for immunosuppression in allotransplanted patients but 
also as a possible antileukemic strategy in combination with intensive  chemotherapy 
or as part of disease-stabilizing treatment at least for the subset of patients with 
 chemokine-responsive AML cells. In this study, we characterized more in detail the 
leukemia cell phenotype of the chemokine-responsive patients. We investigated primary 
AML cells derived from 79 unselected patients. Standardized in vitro suspension cultures 
were used to investigate AML cell proliferation, and global gene expression profiles were 
compared for chemokine responders and non-responders identified through the prolif-
eration assays. CCL28-induced growth modulation was used as marker of chemokine 
responsiveness, and 38 patients were then classified as chemokine-responsive. The 
effects of exogenous CCL28 (growth inhibition/enhancement/no effect) thus differed 
among patients and was also dependent on the presence of exogenous hematopoietic 
growth factors as well as constitutive AML cell cytokine release. The effect of CCR1 
inhibition in the presence of chemokine-secreting mesenchymal stem cells also differed 
among patients. Chemokine-responsive AML cells showed altered expression of genes 
important for (i) epigenetic transcriptional regulation, particularly lysine acetylation; (ii) 
helicase activity, especially DExD/H RNA helicases; and (iii) angioregulatory proteins 
important for integrin binding. Thus, chemokine responsiveness is part of a complex 
Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; cpm, counts per minute; ELISA, enzyme-
linked immunosorbent assay; FAB, French–American–British; Flt3, FMS-like tyrosine kinase 3; Flt3L, Flt3 ligand; GM-CSF, 
granulocyte macrophage colony-stimulating factor; GO, gene ontology; GPCR, G-protein-coupled receptor; GVHD, graft vs. 
host disease; NPM1, nucleophosmin; SCF, stem cell factor; SNF/SW1, sucrose non-fermentable/SWItch.
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AML cell phenotype with regard to extracellular communication and transcriptional 
regulation. Chemokine targeting in chemokine-responsive patients may thereby alter 
AML cell trafficking and increase their susceptibility toward antileukemic treatment, 
e.g., conventional chemotherapy or targeting of other phenotypic characteristics of the 
chemokine-responsive cells.
Keywords: acute myeloid leukemia, chemokine, ccl28, integrin, rna, epigenetic, helicase
inTrODUcTiOn
Acute myeloid leukemia (AML) is an aggressive disease 
 characterized by infiltration of malignant myeloblasts in the bone 
marrow; the only curative treatment is intensive chemotherapy 
potentially in combination with allogeneic stem cell transplanta-
tion (1). However, such intensive treatment is not applicable for 
elderly or unfit younger patients due to an unacceptable risk of 
severe toxicity and treatment-related mortality; immunological 
complications are important causes of the transplant-related 
mortality that can be due to acute graft vs. host disease (GVHD) 
as well as severe infections due to the immunocompromised state 
of patients with chronic GVHD (1).
Several strategies for targeted therapy in AML are now con-
sidered (2, 3). One possibility is to target the AML-supporting 
communication between AML cells and their neighboring 
stromal cells that mediate growth support through their release 
of soluble mediators, including several chemokines (4–11). 
Chemokines are involved in this communication; they may 
function as growth regulators or be important for keeping the 
leukemic cells in their permissive microenvironment and thereby 
render them less susceptible to antileukemic therapy. However, 
in  vitro studies suggest that chemokines function as growth 
regulators in leukemic hematopoiesis only for a subset of AML 
patients, and a wide range of both CCL and CXCL chemokines 
can then modulate leukemia cell proliferation (4). One of these 
chemokines is CCL28 (4) that is released by non-leukemic bone 
marrow stromal cells, and that preserves the functional integrity 
of normal hematopoietic progenitor cells (12) through binding 
to the G-protein-coupled receptors (GPCRs) CCR3 and CCR10 
(13–15). CCR3 is a promiscuous receptor, which can bind several 
ligands in addition to CCL28, whereas CCR10 can only bind 
CCL27 and CCL28 (16).
Our previous studies have identified a subset of patients whose 
AML cells show altered proliferation in the presence of exogenous 
chemokines, and the aim of the present study was to give a broader 
and more detailed characterization of the AML cell phenotype 
for these chemokine-responsive patients. First, chemokine-
responsive patients show growth modulation in the presence of 
several chemokines, including CCL28. We therefore used CCL28 
responsiveness to identify the chemokine-responsive subset 
among 79 unselected patients, and because CCL28 is important 
in normal hematopoiesis, we in addition wanted to characterize 
both the effects of exogenous CCL28 and chemokine receptor 
inhibition in leukemic hematopoiesis as parts of our phenotype 
studies. Second, the phenotype of the chemokine-responsive 
patient subset was further characterized by comparison of 
global gene expression profiles for chemokine-responsive and 
non-responsive patients. A more detailed characterization of this 
phenotype would be necessary in order to design clinical studies 
and decide optimal clinical use of targeted therapy in this subset 
of AML patients.
MaTerials anD MeThODs
aMl Patients and aMl cell Preparation
The study was conducted in accordance with the Declaration 
of Helsinki, and the protocol was approved by the local Ethics 
Committee (Regional Ethics Committee III, University of 
Bergen). Samples were collected after written informed consent. 
AML blasts were derived from 79 consecutive patients (34 females 
and 45 males; median age 67 years with range 18–87 years). Six 
patients had AML relapse (Table 1) and 11 patients had acquired 
AML secondary to previous hematological disease (10 patients) 
or chemotherapy (1 patient). Cytogenetic analyses were available 
for 71 patients; 9 patients had favorable, 6 patients intermediate, 
15 patients adverse, and 41 patients normal cytogenetics, respec-
tively. Our selection of patients and the methods for preparation 
(gradient separation alone) and characterization of AML cells 
have been described in detail previously (17).
Prior to the study, we decided to include 80 unselected patients 
(one patient was left out due to technical reasons); based on a 
previous study (4), we would then expect to identify at least 25 
chemokine responders. This number would be sufficient for sta-
tistical comparisons of functional characteristics as well as global 
gene expression profiles.
The study included only patients with a high percentage 
(>80%) and a high absolute number (>15 × 109/L) of leukemia 
cells among the peripheral blood leukocytes (18). A cell popula-
tion, including >95% AML cells, could then be prepared by 
density gradient separation alone (19). Cells were cryopreserved 
and stored in liquid nitrogen until used in the experiments (19).
Functional In Vitro characterization 
of Primary human aMl cells
All cultures of AML cell alone were prepared in serum-free 
medium (Stem Span, Stem Cell Technologies, Vancouver, 
BC, Canada), and all recombinant cytokines were supplied by 
PeproTech (Rocky Hill, NJ, USA). All exogenous cytokines were 
added at 20 ng/mL, i.e., corresponding to an excess of the added 
cytokine. Our methods for flow-cytometric characterization of 
AML cell viability (20), spontaneous and cytokine-dependent 
proliferation in suspension cultures determined by 3H-thymidine 
incorporation (4, 17), constitutive cytokine release (4), and 
analysis of AML cell viability and proliferation (3H-thymidine 
TaBle 1 | clinical and biological characteristics of the 79 unselected 
patients admitted to our hospital for aMl treatment and included in the 
present study.
Patient characteristics cell morphology cell genetics
Age FAB classification Cytogeneticsa
Median (years) 67 M0 6 Favorable 9
Range (years) 18–87 M1 21 Intermediate 6
M2 11 Normal 41
Gender M3 2 Adverse 15
Females 34 M4 18 n.d. 8
Males 45 M5 15
n.d. 6 Flt3 mutations
Secondary AML ITDb 28
MDS 7 CD34 receptor Wild-type 37
Chemotherapy 1 Negative (≤20%) 21 n.d. 14
CM(M)L 3 Positive (>20%) 53
n.d. 5 NPM1 mutations
AML relapse 6 Mutated 26
Wild-type 40
n.d. 13
aOne of the patients had cytogenetic abnormalities with different prognostic impact; 
inv(16) is associated with a favorable prognosis and +8 with an adverse prognosis. 
Inv(16) is regarded to have the strongest impact and therefore to neutralize the negative 
impact of +8, the patient was classified as having a favorable karyotype.
bOne of the patients has an additional point mutation at D835.
n.d., not determined.
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incorporation) in transwell cocultures with bone marrow 
 mesenchymal stromal cells [(MSC); MSC24539 purchased from 
Lonza, Cambrex BioScience, Walkersville, MD, USA] (8, 9) have 
been described in detail previously. CCL28 levels were deter-
mined by enzyme-linked immunosorbent assay (ELISA) analysis 
(R&D Systems, Abingdon, UK), the minimal detectable level 
being 45 pg/mL. CXCL2 levels were also determined by ELISA 
analysis, whereas the levels of the other chemokines were investi-
gated by Luminex analyses (R&D Systems). The combined CCR1 
and CCR3 antagonist J113863 (R&D Systems) was used at a final 
concentration of 1.5 μM for chemokine receptor inhibition.
rna Preparation and analysis  
of global gene expression
All microarray data were performed using the Illumina iScan 
Reader, which is based upon fluorescent detection of biotin-
labeled cRNA; 300 ng total RNA from each sample was revers-
ibly transcribed, amplified, and labeled with Biotin-16-UTP 
using the Illumina TotalPrep RNA Amplification Kit (Applied 
Biosystems/Ambion, Foster City, CA, USA). Amount and quality 
of the biotin-labeled cRNA were controlled both by NanoDrop 
spectrophotometer and Agilent 2100 Bioanalyzer, before 750 ng 
of biotin-labeled cRNA was hybridized to the HumanHT-12 V4 
Expression BeadChip according to the manufacturer’s instruc-
tions. The chip targets 47,231 probes derived primarily from 
genes in the NCBI RefSeq database (Release 38).
Bioinformatical and statistical analyses
Bioinformatical analyses were performed using the J-Express 
2012 software (MolMine AS, Bergen, Norway). For 
hierarchical clustering of the cytokine secretion, all values were 
 median-normalized and log(10)-transformed. Complete link-
age and Pearson correlation were used as linkage method and 
distance measurement, respectively. The statistical analyses were 
performed with the IBM Statistical Package for the Social Sciences 
(SPSS) version 23 (Chicago, IL, USA). The Mann–Whitney U-test 
was used to compare value distributions among different patient 
groups, and χ2 tests (Pearson’s χ2 test and the likelihood ratio) 
were used to determine correlations between different categories. 
Additionally, Kendall’s tau-b correlation tests were performed 
to determine the agreement between cytokine expression levels 
in cell supernatants and the mRNA levels of these cytokines. 
P-values <0.05 were regarded as statistically significant.
resUlTs
identification of a chemokine-responsive 
Patient subset: exogenous ccl28 Does 
not alter spontaneous In Vitro apoptosis 
but Modulates aMl cell Proliferation for a 
subset of Patients
There was a wide variation among the 79 AML patients with regard 
to the viability of the leukemic cells after 40 h of in vitro culture in 
medium alone (median viability 36%, range 2–81%). The presence 
of 20 ng/mL exogenous CCL28 during culture did not significantly 
alter AML cell viability (median viability 35%, range 3–78%) when 
comparing the overall results (data not shown). Thus, exogenous 
CCL28 does not have any major effect on the regulation of sponta-
neous in vitro apoptosis for primary human AML cells.
Proliferation was analyzed using the 3H-thymidine incorpora-
tion assay, where the nuclide was added after 6 days and nuclear 
activity assayed 24 h later. A median value of at least 1,000 counts 
per minute (cpm) in triplicate cultures was defined as detectable 
proliferation, whereas a significant alteration of 3H-thymidine 
incorporation was defined as (i) an increase/decrease correspond-
ing to at least 20% of the control culture, and the absolute value of 
this change being at least 2,000 cpm for patients with detectable 
proliferation or alternatively, (ii) a change from detectable to 
undetectable proliferation or vice versa (4, 17). We first compared 
AML cell proliferation for cultures prepared in medium alone and 
medium supplemented with 20 ng/mL of CCL28 for all 79 patients. 
The proliferation in medium alone varied among the 79 patients 
(range <1,000–9,191 cpm), and only 17 patients showed detect-
able autocrine (i.e., spontaneous) proliferation. Exogenous CCL28 
increased the proliferation for 14 of the 79 patients compared with 
the corresponding control cultures prepared in medium alone, 
whereas decreased proliferation was seen for 3 patients.
The chemokine-responsive aMl cell 
Phenotype: ccl28-associated growth 
Modulation Depends On the local 
cytokine network
We investigated the effect of CCL28 on growth factor-dependent 
proliferation of primary human AML cells for 56 patients that 
represent a consecutive and thereby unselected subset of the 79 
FigUre 1 | ccl28-associated growth modulation in primary human 
aMl cells; hierarchical clustering analysis of the effects of exogenous 
ccl28 on the spontaneous and gM-csF/scF/Flt3l-dependent 
proliferation of aMl blasts derived from 56 unselected patients. AML 
cells were cultured in medium alone or medium supplemented with 
exogenous GM-CSF, SCF, or Flt3L; for all four types of culture, we compared 
proliferation for cells cultured with and without exogenous CCL28. All 
cytokines were tested at a final concentration of 20 ng/mL. For 14 patients, 
undetectable proliferation (corresponding to a median incorporation of 
<1,000 cpm for triplicate determinations) was detected for all cultures; for 
this reason, we only present the results for the remaining 42 patients. The 
leukemic cells were cultured in suspension cultures, and the proliferation was 
measured as 3H-thymidine incorporation after 7 days of culture.
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patients examined in the autocrine proliferation studies described 
above. The effect of CCL28 was tested in suspension cultures 
prepared either in medium alone or medium supplemented with 
exogenous granulocyte macrophage colony-stimulating factor 
(GM-CSF), stem cell factor (SCF), or FMS-like tyrosine kinase 3 
ligand (Flt3L). A detectable proliferative response for at least one 
of these three growth factors was detected for 42 of the 56 patients, 
and the results for these patients are summarized in the hierarchi-
cal cluster analysis presented in Figure 1 (the analysis also includes 
the effect of CCL28 for cells cultured in medium alone, see above). 
We defined a significant alteration as a difference between the 
CCL28-containing and the corresponding control culture as 
either (i) a change from/to undetectable levels or (ii) a difference 
corresponding to an absolute value of at least 2,000 cpm and in 
addition corresponding to >20% of the respective control culture. 
It can be seen that exogenous CCL28 had divergent effects on 
AML cell proliferation depending on the local cytokine network. 
When using these definitions, we observed a significant growth 
inhibition for 21 and a growth enhancement for 3 out of the 42 
patients in the presence of GM-CSF. In contrast, in the presence 
of Flt3L, significant growth enhancement was seen for 11 patients, 
and growth inhibition was observed for 3 patients. Finally, CCL28 
had generally weaker effects in the presence of SCF; significant 
inhibition was seen only for six patients and enhancement for two 
patients. To summarize, CCL28 can alter the proliferation of pri-
mary human AML cells for a considerable number of patients, this 
effect is highly dependent on the local cytokine network and the 
presence of hematopoietic growth factors, and exogenous CCL28 
altered either autocrine or cytokine-dependent (GM-CSF, Flt3L, 
and SCF) proliferation for 36 of the 56 patients.
CCL28 can bind to the CCR3 and CCR10 receptors (13–15). 
We used our global gene expression profiles (see below) to com-
pare the expression of CCR3 and CCR10, but we could not detect 
any significant difference in receptor expression between patients 
with and without CCL28-associated growth modulation (data 
not shown). These observations suggest that the differences in 
chemokine responsiveness between patients is not caused by dif-
ferent regulation of CCR3/CCR10 expression at the mRNA level.
additional Phenotypic characteristics 
of chemokine-responsive aMl cells: 
constitutive ccl28 release by aMl cells 
is Detected for a Minority of Patients, 
showing Weak association with the 
release of Other chemokines and no 
association with chemokine 
responsiveness
The constitutive release of 11 chemokines was investigated for all 
79 patients (2 × 106 cells/mL, 48 h of in vitro culture). Detectable 
CCL28 release was observed for only 18 patients (median super-
natant level 126 pg/mL, range 49–812 pg/mL), whereas the other 
chemokines were released for most patients (Table  2). When 
comparing the overall results, no significant correlation was seen 
between detectable CCL28 release and cell viability (i.e., spon-
taneous in vitro apoptosis), differentiation [morphological signs 
TaBle 2 | constitutive chemokine release by primary human aMl cells; 
a summary of the results for the 79 unselected patients included in the 
present study.
chemokine # patients with detectable 
release
Median conc. 
(pg/ml)
range  
(pg/ml)
CCL2 67 110 n.d.–9,807
CCL3 79 200 119 to >30,000
CCL4 79 92 21–11,744
CCL5 79 39 7.4–2,481
CCL28 18 n.d. n.d.–812
CXCL1 79 79 41–22,772
CXCL2 69 16 n.d.–11,594
CXCL5 78 95 n.d. to >14,500
CXCL8 79 535 0.3 to >18,500
CXCL10 79 12 1.4–24,642
CXCL11 79 83 25–246
The levels were determined in the culture supernatants after 48 h of in vitro culture for 
the primary AML cells, the supernatant levels of 11 chemokines were determined, and 
the results are presented as the number of patients with detectable release, the median 
level for all 79 patients, and the variation range. CCL28 is highlighted.
n.d., not detected, i.e., below detection limit.
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according to French–American–British (FAB)  classification, 
expression of the CD34 stem cell marker], karyotype, and Flt3 
or NPM1 mutations (data not shown). Finally, there was no 
significant association between constitutive CCL28 release and 
spontaneous/autocrine in  vitro AML cell proliferation, and 
constitutive CCL28 release was seen both for patients with and 
without CCL28-associated growth modulation.
We have previously investigated the constitutive chemokine 
release for a consecutive patient group, and in the present study, 
we also determined the supernatant levels for 10 additional 
chemokines commonly released by primary human AML cells 
at relatively high levels (79 patients). The chemokine levels for 
each individual patient was median-normalized and log(10)-
transformed prior to Pearson clustering in J-Express. The analysis 
is presented in Figure 2. Several chemokines were then grouped 
together in defined subsets. Our previous studies have shown that 
there are three different chemokine subsets characterized by close 
clustering and significant correlations between supernatant levels 
(4); this was also confirmed by our present clustering analysis of 
constitutive chemokine release: (i) CXCL10/11 clustered close 
to CCL5; (ii) CCL2/CXCL1/5/8 clustered close to each other; 
whereas (iii) CXCL2 was the only chemokine tested out of the five 
members of the third cluster and did not cluster close to CCL28 
(4). CCL28 as well as CCL5 clustered as outliers without any strong 
association with other members of the main chemokine clusters.
It can be seen from Figure 2 that the patients could be divided 
into four main subsets/clusters; the two upper subsets generally 
showed high constitutive chemokine release. CCL28-induced 
growth inhibition for cultures prepared with GM-CSF and SCF 
was significantly more frequent in this high chemokine release 
group (15 and 6 out of the upper 42 patients, respectively) 
compared with the low-release group (6/37 and 0/37; likelihood 
ratios = 0.023 and 0.003, respectively). This observation further 
supports our hypothesis from the studies of CCL28 effects in 
the presence of exogenous cytokines (GM-CSF, Flt3L, and SCF, 
see above); the final effects of CCL28 on AML cell proliferation 
depends on the local cytokine network determined by the 
 constitutive cytokine release by the leukemic cells (Figure 2) and 
exogenous cytokines (i.e., cytokines not released by AML cells).
additional Phenotypic characterization of 
aMl cells: normal Blood cell counts at 
Diagnosis Do not Differ among Patients with 
and without constitutive ccl28 release
Bone marrow failure with pancytopenia in peripheral blood 
is common at the time of diagnosis for AML patients (1). 
Furthermore, CCL28 is a growth and survival factor for normal 
hematopoietic cells (12), and for this reason we compared periph-
eral blood hemoglobin levels and platelet counts at the time of 
diagnosis for patients with and without constitutive CCL28 
release by their AML cells. We could not detect any significant 
difference between the two groups with regard to Hb levels or 
platelet counts at the time of diagnosis (data not shown).
additional Phenotypic characterization of 
chemokine-responsive Patients: chemokine 
receptor Blocking has antileukemic effects 
Only for certain Patients
We investigated the effects of endogenous chemokines using an 
in vitro model, where primary human AML cells and normal bone 
marrow MSCs derived from a healthy donor were separated by 
a semipermeable membrane during coculture (9); the MSCs can 
then influence AML cell proliferation only through their release 
of soluble mediators. We tested the effects of the combined CCR1 
(ligands being CCL2/3/5/7/14/15/16/23/28) and CCR3 (ligands 
being CCL5/7/8/11/13/15/24/28) antagonist J113863 on AML 
cell viability and proliferation; viability was investigated by a flow-
cytometric assay and proliferation as 3H-thymidine incorporation 
(8, 9). We investigated this pharmacological effect for primary 
AML cells derived from five CCL28/chemokine responders. The 
inhibitor had divergent effects on AML cell proliferation during 
coculture with chemokine-releasing MSCs; for one patient, growth 
inhibition was seen (median proliferation corresponding to 9,457 
vs. 3,502  cpm), for three other patients, increased proliferation 
was observed (21,323 vs. 26,253 cpm, 10,934 vs. 19,713 cpm, and 
55,257 vs. 74,956 cpm, respectively), and for the last patient, only 
a minor effect of CCL28 was seen (4,800 vs. 4,392 cpm) in the 
cocultures. These experiments show that chemokines mediate 
divergent effects on AML cell proliferation that differs among 
the chemokine responders also, when tested in the presence of 
cytokine/chemokine-releasing bone marrow MSCs.
additional Phenotypic characterization 
of chemokine-responsive Patients: 
chemokine responsiveness is associated 
with altered expression of genes 
important for Protein acetylation, helicase 
activity, and integrin Binding
In a previous study, we observed that CCL28 could modulate 
AML cell proliferation only for a subset of patients (4); this was 
FigUre 2 | The constitutive chemokine release profile by primary human aMl cells. The constitutive release of 11 chemokines, including CCL28, during 
in vitro culture was examined for primary human AML cells derived from 79 consecutive patients. Chemokine release was determined as the protein level in culture 
supernatants. Based on the hierarchical clustering analysis, the patients could be divided into four subclusters. CCL28, together with CCL5, formed an out-group 
and did not correlate with the expression of the other nine chemokines. The column on the right shows the 14 patients whose cells responded with increased 
proliferation to CCL28 (green) in medium alone without supplementation of exogenous growth factors, and the 3 patients whose blasts showed reduced proliferation 
in the presence of CCL28 compared to cultures containing only medium (blue).
6
Brenner et al. Chemokine Responsiveness in Human AML
Frontiers in Immunology | www.frontiersin.org May 2016 | Volume 7 | Article 205
TaBle 3 | comparison of global gene expression profiles for primary 
human aMl cells with and without chemokine-induced growth 
modulation – a summary of the differentially expressed genes encoding 
proteins important for integrin binding (for additional details, see 
Table s1 in supplementary Material).
classification of genes based on the protein function angioregulation 
vascular biology
Proteases
ADAM2, a disintegrin and metallopeptidase (ADAM) 
domain 2
+
ADAM23, ADAM metallopeptidase domain 23 +
ADAM22, ADAM metallopeptidae domain 22 +
ADAMTS8, ADAM metallopeptidase with thrombospondin 
type 1 motif 8
+
extracellular matrix molecules
COL3A1, collagen type III alpha 1 +
COL5A1, collagen type V alpha 1 (vascular stability)
COL16A1, collagen type XVI alpha 1
FBLN5, fibulin 5 +
LAMA5, laminin alpha 5 +
LAMB2, laminin beta 2 (angioregulator) +
TNN, tenascin N +
soluble mediators involved in angiogenesis
ANGPTL1, angiopoietin-like 1 +
CYR61, cysteine-rich angiogenic inducer 61 +
JAM3, junctional adhesion molecule 3 (the soluble form)
VWF, von Willebrand factor +
cell-to-cell and cell-to-matrix adhesion
ICAM3, intercellular adhesion molecule 3 (LFA-1 ligand) +
ITGB1BP1, integrin beta 1 binding protein 1 +
ITGB6, integrin beta 6 +
JAM3, junctional adhesion molecule 3 +
THBS4, thrombospondin 4 +
THY1, Thy-1 cell surface antigen +
Other genes encoding proteins involved in angiogenes
EMP2, epithelial membrane protein 2 (integrin modulator) +
KDR, kinase insert domain receptor (VEGF receptor) +
NMB (neuromedin B) +
SOD1, superoxide dismutase 1, soluble +
Other genes
IMPAD1, inositole monophosphatase domain containing 1
OXCT1, 3-oxoacid transferase 1 (mitchondrial metabolism)
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also confirmed in our present study (Figure  1). The previous 
study showed that for this particular patient subset, AML cell 
proliferation could be modulated not only by CCL28 but also by 
several other chemokines binding to different chemokine recep-
tors (4). Thus, CCL28 growth modulation should be regarded as 
a marker of a patient subset that, in contrast to other patients, are 
characterized by chemokine-induced (GPCR-mediated) growth 
modulation. We then compared the global gene expression 
profiles for 37 unselected patients; 15 of these patients being clas-
sified as responders, according to the definitions used above for 
the effects of exogenous CCL28 on spontaneous and/or growth 
factor-dependent (GM-CSF, Flt3L, and SCF) proliferation. 
However, with regard to the classification of patients as respond-
ers/non-responders and the change to/from undetectable from/
to detectable proliferation (i.e., proliferation corresponding to 
>1,000  cpm defined as detectable, see above), this definition 
is arbitrary and four of the seven patients with such a change 
showed a relatively small absolute difference between cultures 
with and without exogenous CCL28. Even though there was a 
change from undetectable to detectable with CCL28, two of these 
four patients therefore were by chance classified as responders 
and the two others as non-responders.
We first identified those genes showing a difference between 
the two patient subsets corresponding to p < 0.001 and a false 
discovery rate (FDR) of <0.01. The identified genes (21) were 
included in 20 gene ontology (GO)-terms; a major part of 
these terms were associated with integrin binding (Table  3, 
Table S1 in Supplementary Material), protein/lysine/histone 
acetylation (Table  4, Table S2 in Supplementary Material), or 
helicase activity (Table 5, Table S3 in Supplementary Material). 
The term integrin binding included 27 differentially expressed 
genes; among them were several proteases and angioregulatory 
mediators, seven genes encoding extracellular matrix molecules, 
and several adhesion molecules. The large part of the proteins 
encoded by these genes seems to play a role in the regulation of 
local angiogenesis, a process important both for the development 
and chemosensitivity of human AML (8). Integrins may also be 
important for modulation of intracellular signaling initiated by 
ligation of the CCR3 chemokine receptor (22). Second, the terms 
histone acetylation, lysine-protein acetylation, and internal 
peptidyl lysine acetylation were overlapping and included 48 
genes; a large number of them are involved in histone modula-
tion/acetylation and/or in transcriptional regulation (Table  4, 
Table S2 in Supplementary Material). Finally, the largest group 
of differentially regulated genes were included in the GO term 
Helicase Activity (Table 5, Table S3 in Supplementary Material). 
This group included mainly RNA helicases (e.g., 23 members 
of the DEAD box family RNA helicases together with several 
DEAH box family RNA helicases), mini-chromosome mainte-
nance proteins, and members of the sucrose non-fermentable/
SWItch (SNF/SW1) family.
DiscUssiOn
Several recent studies have emphasized the importance of inves-
tigating the cancer cell phenotype for understanding carcino-
genesis, defining patient subsets in heterogeneous malignancies, 
and identifying possible therapeutic targets (23–25). The  aim 
of the present study was therefore to characterize the AML 
cell phenotype more in detail for the subset of patients having 
chemokine-responsive leukemic cells. Our present observations 
suggest that these patients respond to exogenous chemokines and 
combination of chemokine/chemokine receptor targeting either 
with other targeted therapies (e.g., epigenetic or integrin-target-
ing) or conventional chemotherapy may therefore be considered 
especially for the identified patient subset.
Chemokine receptor blockers can be used as an immunosup-
pressive strategy, e.g., as GVHD therapy in AML patients receiving 
allogeneic stem cell transplantation (21). Chemokine targeting 
may thus be used in these patients (i) as a pre-/posttransplant 
antileukemic strategy with direct effects on the leukemic cells at 
least for patients with chemokine-responsive cells or (ii) as an 
immunosuppressive treatment. GVHD has antileukemic effects, 
and immunosuppression due to severe GVHD will reduce this 
effect. However, at least for patients with chemokine-responsive 
TaBle 5 | comparison of global gene expression profiles of primary 
human aMl cells with and without chemokine-induced growth 
modulation – a summary of the differentially expressed genes encoding 
proteins important for helicase activity.
classification of genes based 
on the protein structure and/or 
function
Dna rna Trans.
DeaD box family of proteins (rna helicases)
DDX4, DDX10 (involved in 
leukemogenesis?), DDX17, DDX18 
(activated by Myc)
+
DDX27/50/51/52/54/58/60/60L
DOX19A +
IFIH1 +
DDX3X/6/28 + +
Deah box family of proteins
DHX8/9/40 +
DHX29
WRN (DNA repair?) +
Mini-chromosome maintenance proteins (genome replication)
MCMDC1 (chromatin modulation)
MCM7/9
MCM8 +
snF/sW1 family of protein (chromatin remodeling)
ATRX +
HLTF +
SMARCA2, SMARCA4, SMARCAL1 +
Other helicases
CHD3 (histone deacetylation) +
CHD4 (histone deacetylation) + +
CHD6 (chromatin remodeling) +
CHD8 (chromatin remodeling) + +
CHD9 +
MOV10 +
HELZ +
Proteins involved in Dna methylation, chromatin remodeling, and Dna 
repair
ASCC3 (DNA repair)
ERCC8 (DNA repair), SHPRH (DNA 
repair?), SRCAP (histone remodeling)
+
Other genes/proteins
EIF4A1
EP400 (protein synthesis?)
GTF2F2 +
JARID2 (mutations associated with 
myeloid malignancies)
+
PRIC285
RAD54L2
TDRD12
YTHDC2
ZRANB3 (DNA repair?)
Additional characteristics that possibly are important for leukemogenesis are given in 
parenthesis at the end of the functional description (for additional details, see Table S3 
in Supplementary Material). To the right in the figure is indicated whether the proteins 
are important for the function of DNA, RNA function/metabolism, or transcriptional 
regulation.
TaBle 4 | a comparison of the global gene expression profiling of 
primary human aMl cells with and without chemokine-induced growth 
modulation – a summary of the differentially expressed genes that 
encode proteins important for histone acetylation (for additional details, 
see Table s2 in supplementary Material).
Main classification based on the protein function
gene identity
chromatin modulation/histone acetylation and transcriptional 
regulation
ACTL6A, CHD9, DMAP1, EPC1, ING3, KAT2A, KAT2B, KIAA1267, MEAF6, 
MLL, MYST1, MYST2, MYST4, SRCAP, SMARCA4, TRRAP, YEATS2
Transcriptional regulation only
BRD8, BRPF1, CHD9, GTF3C4, EP400, HCFC1, LDB1, MECP2, MYOD1, 
OGT, PHD15, PHD16, PHF17, PHF20, TAF1, TAF1L, TAF6L, TAF15, TCF3
Dna repair
BRCA2, HCFC1, PHF20, TRRAP
cell cycle regulation
HCFC20
genes with other or unknown functions
BAT3 (apoptosis), CCDC101, CPA3 (protease), KIAA1310, MBIP, MSL2, 
USP22
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AML cells, the use of chemokine targeting may represent a thera-
peutic alternative that reduces the GVHD-associated antileuke-
mic reactivity but at the same time has an additional antileukemic 
effect by itself against residual AML.
Acute myeloid leukemia is a heterogeneous and aggres-
sive disease, and in a previous study of another smaller 
patient population, we observed that exogenous CCL28 could 
modulate cytokine-dependent AML cell proliferation for a 
minority of patients. For this patient subset, CCL28 was one 
out of several chemokines with growth-modulating effect (4). 
Several chemokine receptor inhibitors are now available, and 
this strategy is considered in the treatment of AML both as an 
AML-directed antileukemic treatment or as an immunosuppres-
sive strategy for patients with immune-mediated complications 
following allogeneic stem cell transplantation (21). In the present 
article, we have studied a large group of patients more in detail, 
and for these patients, the growth modulation seems to be a 
part of a wider phenotype that also includes altered epigenetic/
transcriptional regulation, RNA metabolism/splicing, and local 
regulation of angiogenesis. Many chemokines and chemokine 
receptors show promiscuous receptor/ligand binding, and tar-
geting of single chemokines may therefore have limited effect 
because a wide range of chemokines are present in the bone mar-
row microenvironment (9). Combined targeting with different 
GPCR antagonists or combination with agents that target other 
aspects of this complex phenotype may then be considered for 
this particular subset of patients.
CCL28 is a chemokine involved in normal hematopoiesis 
(12). We now describe that it can also be involved in leukemic 
hematopoiesis and modulate the growth of primary human AML 
cells for a subset of patients. However, its final effect depends on 
the local cytokine network. Growth inhibition was observed in 
the presence of the exogenous cytokines, SCF and especially 
GM-CSF, whereas growth enhancement was seen in the presence 
of exogenous Flt3L. Finally, CCL28 can be constitutively released 
by primary human AML cells and thereby be a part of the cross 
talk between leukemic cells and their neighboring bone mar-
row cells, but the ability of constitutive CCL28 release showed 
no association with autocrine proliferation or the effects of 
 exogenous CCL28.
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We included 79 patients in the present study, and they  represent 
a consecutive and thereby unselected group, except that all of 
them showed relatively high levels of circulating AML cells. This 
strategy was used to allow a standardized preparation of highly 
enriched AML cells by gradient separation alone, thereby avoid-
ing the risk of inducing functional alterations in the cells by more 
extensive separation procedures (17). The use of this strategy has 
been discussed previously (17), and our study population does 
not differ from the overall patient population regarding important 
biological, clinical, and prognostic parameters (4) (see below).
In our study, we investigated primary AML cells from 
consecutive/unselected patients. These cell populations have a 
hierarchical organization with (i) a majority of more mature cells 
undergoing stress-induced apoptosis during in vitro culture; (ii) 
an intermediate subset of clonogenic progenitors (often <1%); 
and (iii) a small minority of AML stem cells (18, 26). Studies 
of the total cell population should still be regarded as relevant 
despite this organization, especially with regard to antileukemic 
therapy, because: (i) early morphological disease control with 
remission induction (i.e., reduction of the total AML cell popula-
tion) is an important prognostic parameter (1); (ii) clinical studies 
have shown that biological characteristics of the total AML cell 
population reflect general leukemic cell characteristics that have 
prognostic impact and are essential for leukemogenesis and che-
mosensitivity (26); and (iii) previous studies have also shown that 
the AML stem cells can be detected in various subsets, usually in 
the CD34+CD38− subset and also in the CD34− and CD34+CD38+ 
subsets, and stem cell characteristics are also reflected in the 
overall cell population (18, 26).
All our methods for cell preparation, in vitro culture, and AML 
cell characterization have been described in previous methodo-
logical investigations. First, our approach with inclusion of only 
patients with relatively high peripheral blood AML cell counts 
have been characterized previously when consecutive patients 
with high blood AML cell counts were compared with the overall 
consecutive AML patient population (17). The two groups did 
not differ with regard to other prognostic (i.e., chemosensitivity) 
parameters, but despite this, one should be careful when general-
izing from our results (17). Second, the use of cryopreservation has 
also been discussed previously, and its effect on AML cell viability 
has been described in detail (19, 20). Third, we used serum-free 
medium for culture of AML cells (27), the only exception being 
the cocultures with MSCs, because these mesenchymal cells 
require an enriched medium (9). Finally, as described above, the 
AML cell population has a hierarchical organization (26), and our 
proliferation assay based on 3H-thymidine incorporation allows 
us to analyze only the proliferation of long-term surviving cells 
able to proliferate after 7 days of culture; these cells represents an 
enrichment of clonogenic cells (18). Thus, our study is based on 
well-characterized and standardized methodological strategies.
Chemokine receptor inhibitors are now being developed 
(28,  29). However, patients showing chemokine-dependent 
growth modulation usually respond to a wide range of chemokines 
that bind different receptors (4), and both the constitutive 
chemokine/cytokine release by AML cells and the release by 
neighboring bone marrow stromal cells will determine the final 
effect of chemokine receptor binding on AML cell proliferation. 
These observations suggest that combined targeting of promis-
cuous chemokine receptors would be most effective in AML. 
However, the intracellular signaling downstream to the various 
chemokine receptors is difficult to predict (16, 22), and our pre-
sent results show that even such broad targeting of a promiscuous 
receptor has divergent effects for chemokine-responsive patients. 
It is not known whether combined targeting of the other pheno-
typic characteristics of these patients will be more effective.
Constitutive CCL28 release was observed for a minority of 
patients and showed no correlation with autocrine proliferation, 
chemokine responsiveness, or gene expression profiles. Despite 
these observations, CCL28 may contribute to leukemogenesis 
or chemosensitivity through its effect on neighboring stromal 
cells. Recent studies have demonstrated that CCR3 and CCR10 
receptors are expressed by bone marrow stromal cells (30). The 
bone marrow microenvironment is hypoxic, and studies in 
experimental models strongly suggest that CCL28 is important 
for cell trafficking and angiogenesis in hypoxic microenviron-
ments associated with carcinogenesis (31). CCL28 is also released 
by endothelial cells and may thereby be a part of the cross talk 
between AML and neighboring stromal cells. Through its release 
by non-leukemic stromal cells in the bone marrow microenvi-
ronment (7, 32), CCL28 may still function as a growth factor 
for remaining normal hematopoietic cells in AML (12). Finally, 
as discussed below, there may also be an interaction between 
integrins and CCL28, as the latter promotes integrin-dependent 
cell adhesion (33).
We investigated the effect of CCR1/CCR3 inhibition (both 
being promiscuous receptors) in a more physiological model of 
AML/MSC cocultures; this model was used to study chemokine 
effects in a local cytokine network with a major influence of 
bone marrow stromal elements. Our results show that even in a 
cytokine environment formed by the constitutive cytokine release 
and the cytokine-mediated cross talk between primary AML and 
bone marrow MSCs, the CCR1/CCR3-mediated effects on AML 
cell proliferation are divergent, and the different effects of CCR1/
CCR3 inhibition on AML cell viability and proliferation can be 
explained by the hierarchical organization of the AML cell popu-
lation (17). The viability studies then reflect the characteristics 
of the majority of more mature cells that undergo spontaneous 
apoptosis during the first days of culture, whereas the prolif-
eration is assayed after several days of culture and reflects the 
ability of a more immature cell minority capable of maintaining 
proliferation after several days.
Even though we could not detect effects of chemokine inhibition 
on AML cell proliferation in vitro, studies in chronic lymphocytic 
leukemia (CLL) have shown that altered regulation of in vivo cell 
trafficking can contribute significantly to the antileukemic effects 
of certain drugs (34–39). The microenvironment is important both 
for survival and proliferation of CLL cells, and local chemokine 
release is a part of this support. Furthermore, ibrutinib mediates 
its antileukemic effect in CLL through direct effects on the CLL 
cells and through inhibition of chemokine-dependent leukemia 
cell trafficking, thereby keeping the cells out of their growth-
enhancing/antiapoptotic microenvironment and making them 
susceptible to the direct antileukemic effect. Our present study 
shows that a subset of patients has chemokine-responsive AML 
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cells, and similar dual-targeting may be possible in AML. This 
hypothesis is supported by recent studies; ibrutinib has direct 
antileukemic effects in human AML (40) and is in addition able 
to alter chemokine-dependent AML cell migration (41). Our 
present studies therefore suggest combined targeting of AML 
cell survival, and migration (i.e., chemokine targeting) should be 
considered for patients with chemokine-responsive AML cells.
In our studies of global gene expression profiles, we observed 
that AML cells with CCL28-induced growth modulation (i.e., 
chemokine-responsive) showed an altered expression of genes 
included in the GO-terms lysine acetylation/integrins/helicases. 
As discussed above, there is a functional interaction between 
CCL28 and integrins, but there is also a biological interaction 
between the integrin system and lysine acetylation. First, histone 
acetylation is important for regulation of gene expression (2, 42), 
including the expression of integrins in human AML cells (43). 
Second, lysine acetylation can also alter integrin expression indi-
rectly; HOX transcription factors are important for regulation of 
integrin gene expression, and acetylation is then important in the 
regulation of HOX activity both through effects on the mRNA 
expression of these transcription factors and through modula-
tion of their transcription factor activity by posttranscriptional 
modulation of HOX proteins (44, 45). Third, experimental 
studies suggest that integrins can mediate intracellular signaling 
that alters histone acetylation and thereby alter the proliferation 
of malignant cells (46, 47). Through this signaling, integrins can 
also regulate gene expression in human myeloid cells through the 
activation of several transcription factors (48). Finally, acetyla-
tion of microtubules is important for regulation of the cell surface 
density of integrins (49). Thus, through their interactions with 
extracellular matrix and neighboring cells, integrins mediate 
bidirectional signaling, i.e., inside-out and outside-in signaling 
(50, 51), and lysine acetylation is important at several steps of 
this process.
Helicases are also important for transcriptional and trans-
lational regulation and thereby seem to represent a functional 
overlap with lysine acetylation. First, a major part of the helicases 
with altered expression are members of the DEAD box family 
of RNA helicases, they belong to the helicase superfamily 2 
together with the DEAH helicases and are often referred to as 
DExD/H box RNA helicases (52, 53). The helicases should be 
regarded as multifunctional proteins important in regulation of 
transcription, ribosome biogenesis, translation, and RNA decay/
storage/metabolism; they also have ATPase activity and can func-
tion as metabolic sensors (53–55). The helicase DDX10 can be 
involved in leukemogenesis (56). Second, the mini-chromosome 
maintenance complex forms an important part of the replication 
machinery, but its loading to chromatin at sites distant from rep-
licating DNA strongly suggests that it has additional functions, 
possibly as transcriptional regulators (57). Third, SWI/SNF is 
a multisubunit chromatin-remodeling complex important for 
regulation of cell cycle progression, apoptosis, differentiation, 
genomic instability, and DNA repair (58). The function of this 
molecular complex in AML seems to differ from other malignan-
cies, and it is considered as a possible therapeutic target in human 
AML (59, 60).
cOnclUsiOn
Chemokines have growth-modulating effects on the AML cells 
only for a minority of patients; and these patients are then 
responsive to several chemokines. However, this chemokine 
responsiveness is only a part of a more extensive leukemia cell 
phenotype that includes several partly interacting cellular func-
tions, i.e., altered extracellular communication (chemokines/
integrins/acetylation) and transcriptional regulation (histone 
acetylation, helicases) compared with the other non-responsive 
AML cells. Furthermore, the direct effects of chemokine 
targeting on primary human AML cells are difficult to predict 
because they depend both on differences among patients and 
on the overall local cytokine network; this is probably true both 
if chemokine targeting is tried as an antileukemic strategy or 
as an approach to treat immune-mediated complications in 
allotransplanted AML. A careful evaluation of the AML cells will 
possibly be important to avoid the risk of leukemia enhance-
ment and thereby increased relapse risk; this would probably 
be important if the treatment is tried both as an antileukemic 
and an immunosuppressive strategy. A possible approach to 
avoid this risk may be combined targeting of other aspects of 
this complex phenotype. However, based on the lessons from 
recent studies in CLL where chemokines are important for the 
supportive function of neighboring stromal cells by keeping 
the CLL cells within their permissive microenvironment, one 
would emphasize that AML cells from chemokine-responsive 
patients should be further tested in relevant in vivo models (e.g., 
patient-derived xenografts) to see whether chemokine targeting 
alters AML cell trafficking/homing and thereby increases their 
chemosensitivity.
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